非酒精性脂肪性肝病的代谢驱动因素。
Metabolic drivers of non-alcoholic fatty liver disease.
机构信息
Internal Medicine Research Unit, Pfizer Worldwide Research, Development, and Medical, Cambridge, MA, USA.
Internal Medicine Research Unit, Pfizer Worldwide Research, Development, and Medical, Cambridge, MA, USA.
出版信息
Mol Metab. 2021 Aug;50:101143. doi: 10.1016/j.molmet.2020.101143. Epub 2020 Dec 17.
BACKGROUND
The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide parallel to the global obesity epidemic. NAFLD encompasses a range of liver pathologies and most often originates from metabolically driven accumulation of fat in the liver, or non-alcoholic fatty liver (NAFL). In a subset of NAFL patients, the disease can progress to non-alcoholic steatohepatitis (NASH), which is a more severe form of liver disease characterized by hepatocyte injury, inflammation, and fibrosis. Significant progress has been made over the past decade in our understanding of NASH pathogenesis, but gaps remain in our mechanistic knowledge of the precise metabolic triggers for disease worsening.
SCOPE OF REVIEW
The transition from NAFL to NASH likely involves a complex constellation of multiple factors intrinsic and extrinsic to the liver. This review focuses on early metabolic events in the establishment of NAFL and initial stages of NASH. We discuss the association of NAFL with obesity as well as the role of adipose tissue in disease progression and highlight early metabolic drivers implicated in the pathological transition from hepatic fat accumulation to steatohepatitis.
MAJOR CONCLUSIONS
The close association of NAFL with features of metabolic syndrome highlight plausible mechanistic roles for adipose tissue health and the release of lipotoxic lipids, hepatic de novo lipogenesis (DNL), and disruption of the intestinal barrier in not only the initial establishment of hepatic steatosis, but also in mediating disease progression. Human genetic variants linked to NASH risk to date are heavily biased toward genes involved in the regulation of lipid metabolism, providing compelling support for the hypothesis that NASH is fundamentally a metabolic disease.
背景
非酒精性脂肪性肝病(NAFLD)的发病率与全球肥胖症的流行呈平行上升趋势,在全球范围内迅速增加。NAFLD 涵盖了一系列肝脏病理,并且通常起源于肝脏中脂肪的代谢驱动积聚,即非酒精性脂肪肝(NAFL)。在 NAFL 患者的亚组中,疾病可能进展为非酒精性脂肪性肝炎(NASH),这是一种更严重的肝脏疾病,其特征为肝细胞损伤、炎症和纤维化。在过去十年中,我们对 NASH 发病机制的理解取得了重大进展,但在疾病恶化的确切代谢触发因素的机制知识方面仍存在差距。
综述范围
从 NAFL 向 NASH 的转变可能涉及肝脏内外多种因素的复杂组合。本篇综述重点关注 NAFL 发病和 NASH 早期阶段中早期代谢事件。我们讨论了 NAFL 与肥胖的相关性,以及脂肪组织在疾病进展中的作用,并强调了与肝脂肪堆积向脂肪性肝炎的病理转变相关的早期代谢驱动因素。
主要结论
NAFL 与代谢综合征的特征密切相关,这突出了脂肪组织健康和脂毒性脂质释放、肝从头脂肪生成(DNL)以及肠道屏障破坏的潜在机制作用,不仅在肝脂肪变性的初始建立中,而且在介导疾病进展中。迄今为止,与 NASH 风险相关的人类遗传变异主要偏向于参与脂质代谢调节的基因,这为 NASH 从根本上是一种代谢性疾病的假说提供了有力支持。